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self-reported disease activity and better
health-related quality of life in female rheumatoid
arthritis patients in Sweden: data from BARFOT,
a multicenter study on early RA
Stefan Bergman1,2*, Sofia Symeonidou2, Maria L Andersson2, Maria K Söderlin2 and for the BARFOT study groupAbstract
Background: Earlier studies have found a positive effect of alcohol consumption, with a reduced disease activity in
rheumatoid arthritis (RA). The aim of this study was to assess alcohol consumption and its association with disease
activity and health related quality of life (HRQL) in Swedish RA patients.
Methods: Between 1992 and 2005, 2,800 adult patients were included in the BARFOT study of early RA in Sweden.
In 2010 a self-completion postal questionnaire was sent to all 2,102 prevalent patients in the BARFOT study
enquiring about disease severity, HRQL, and lifestyle factors. Alcohol consumption was assessed using the validated
AUDIT-C questionnaire.
Results: A total of 1,238 out of 1,460 patients answering the questionnaire had data on alcohol consumption: 11%
were non-drinkers, 67% had a non-hazardous drinking, and 21% were classified as hazardous drinkers. Women who
drank alcohol reported lower disease activity and better HRQL, but there were no association between alcohol
consumption and disease activity in men. For current smokers, alcohol use was only associated with fewer
patient-reported swollen joints. The outcome was not affected by kind of alcohol consumed.
Conclusions: There was an association between alcohol consumption and both lower self-reported disease activity
and higher HRQL in female, but not in male, RA patients.
Keywords: Rheumatoid arthritis, Alcohol, EULAR response criteria, Health-related quality of lifeBackground
Alcohol has been shown to have immunosuppressive ef-
fects in mouse models [1]. Two large studies from the UK
and Switzerland on rheumatoid arthritis (RA) patients
have reported positive effects of moderate drinking, with a
reduced disease activity and a better outcome in RA [2,3].
The Swiss study showed that alcohol had significant posi-
tive effects with less radiographic progress in men, but not
in women [3]. Drinking has also been reported to be* Correspondence: stefan.bergman@spenshult.se
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reproduction in any medium, provided the orassociated with lower risk of developing RA [2,4,5]. It is
not known whether the kind of alcohol has any influence
on disease activity in RA.
Little is known about alcohol consumption and its as-
sociation with disease activity in Swedish RA patients.
The aim of this study was to assess alcohol consumption
and its association with disease activity and health re-
lated quality of life (HRQL) in a large longitudinal obser-
vational study of Swedish RA patients. Our hypothesis
was that moderate drinking would be associated with
better HRQL and less pain. We also hypothesized that
RA patients who drank heavily would have poorer
HRQL and function. A second aim was to determine
whether there were any gender differences regarding theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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kind of alcohol the patients drank was associated with
disease activity. We hypothesized that wine drinkers
would have a particularly good outcome.
Methods
During the period 1992–2005, 2,800 patients over 18
years of age were enrolled in the BARFOT (Better Anti-
Rheumatic FarmacOTherapy) study, a multicenter lon-
gitudinal observational study of patients with early RA
in southern Sweden [6-8]. All patients fulfilled the
American College of Rheumatology RA classification
criteria from 1987 [9] and in this study all patients had
a disease duration of ≤ 2 years. Disease activity was eval-
uated at inclusion, at 3, 6, and 12 months, and at 2, 5, 8,
and 15 years. Treatment with disease-modifying anti-
rheumatic drugs (DMARDs), glucocorticoids and bio-
logics was registered at all follow-up points. Between
March and September 2010, all patients who were still
alive in the BARFOT study (n = 2,102) received a self-
completion postal questionnaire with visual analog
scales (VAS) for general health and pain, the Swedish
version of the Health Assessment Questionnaire (HAQ)
[10,11], patient-reported swollen joint counts (SJCs)
and tender joint counts (TJCs) (of 28), assessment of
lifestyle factors such as smoking and alcohol consump-
tion, and current and past medication with DMARDs,
glucocorticoids, and biologics. Health-related quality of
life (HRQL) was assessed using the EQ-5D (EuroQol).
Part 1 of the EuroQol questionnaire assesses self-reported
problems involving 5 domains: mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression. Each
domain is divided into 3 levels of severity: no problem,
some problems, and extreme problems. A time-tradeoff
procedure in a normal adult population (with 3,395 re-
spondents) in the UK has been used to obtain EuroQol
utility weights that vary between 1 and −1 [12-16].
Drinking was assessed with the AUDIT-C [17-20],
which is a validated subset of the consumption items of
the full AUDIT (Alcohol Use Disorder Investigation Test)
[21-26]. The AUDIT-C has been shown to outperform the
full AUDIT instrument when measuring high-volume
drinking [21,27].
The AUDIT-C questionnaire consists of three ques-
tions, giving a total score of 0 to 12 points:
(1)How often do you have a drink containing alcohol?
Never (0 points), Once a month or even less often
(1 point), 2–4 times a month (2 points), 2–3 times a
week (3 points), and 4 times a week or more
(4 points).
(2)How many standard drinks containing alcohol do you
have on a typical day? 1-2 (0 points), 3–4 (1 point), 5–
6 (2 points), 7–9 (3 points), and 10 or more (4 points).(3)How often do you have six or more drinks on one
occasion? Never (0 points), Less often than once a
month (1 point), Every month (2 points), Every week
(3 points), and Daily or almost daily (4 points).
The Swedish National Institute of Public Health has
set limits for hazardous drinking at AUDIT-C ≥ 4 points
for women and ≥ 5 points for men www.fhi.se and per-
sonal communication . In this study, these patients were
labelled hazardous drinkers. Non-hazardous drinkers in
this study were patients who did drink alcohol, but who
had less total points in the AUDIT-C than hazardous
drinkers.
Patients were also asked to tick in a box “What do you
prefer to drink when you drink alcohol? (beer/wine/
spirits)”. Some patients ticked more than one box, and
these patients were classified as “mixed” drinkers. The
postal questionnaire in 2010 had a picture associated
with these questions showing that one “drink” of alcohol
corresponds to 500 ml of light beer, 330 ml of strong
beer, 100–150 ml of red or white wine, 50–80 ml of for-
tified wine (e.g. sherry), or 40 ml of spirits, e.g. whisky.
Smoking status was recorded at the time of the postal
questionnaire in 2010 (never-smokers, current smokers,
and previous smokers). Occupation was also recorded and
coded according to the latest version of the Categorization
of Socioeconomic Status (Socioekonomisk indelning, SEI)
in Sweden. The socioeconomic status of workers was clas-
sified as blue-collar, lower white-collar, upper white-collar,
self-employed, and other occupation according to the SEI.
Altogether, two reminders were sent to the patients
who did not respond to the first and second mailing of
the self-completed questionnaire in 2010. All patients
received written information about the questionnaire in
2010, and the Ethical Committee of Lund University ap-
proved the BARFOT study and the self-completed postal
questionnaire in 2010.
Statistics
Statistical analyses were performed using SPSS 18.0 sta-
tistical software. All significance tests were two-tailed
and were conducted at the 5% significance level. To test
differences between groups, Mann–Whitney test or the
independent t-test was used for continuous variables
and the chi-square test was used for proportions. For
non-parametric values, Kruskall-Wallis test was used to
analyze differences between the different drinking catego-
ries. Pairwise Kruskall-Wallis post hoc analyses were
performed to determine which variables differed signifi-
cantly from each other, stratified for the different drinking
categories. Post hoc analyses using standardized residuals
were used to assess the differences in DMARD treatment
and differences between sexes, stratified according to
alcohol consumption. Multiple logistic regression analyses
(
)
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an independent predictive factor for a score over the
median value of HAQ, EuroQol, and VAS global health in
the 2010 questionnaire. The following variables were in-
cluded in the regression analyses at the time of the 2010
questionnaire: drinking (none, non-hazardous, hazardous),
age, sex, disease duration, smoking (no, previous, current),
SEI class (blue-collar, lower white-collar, upper white-
collar, self-employed, other), and number of previous
DMARDs and biologics. There was no colinearity in the
variables entered into the multiple logistic regression
analyses.
Results
Altogether, 1,460 patients who had answered the 2010
self-completion postal questionnaire and who were > 18
years of age and had a disease duration of ≤ 24 months
were included in this study. The patient-reported disease
activity and demographics from the postal questionnaire
in 2010 are shown in Table 1.
Patients who did not answer the 2010 questionnaire
(579/2104, 27.5%) had higher mean DAS28 (5.4 for non-
responders vs. 5.2 for responders, p = 0.01), higher mean
VAS health (48 mm vs. 45 mm, p = 0.008), higher mean
number of SJCs (11 vs. 10, p = 0.03) at inclusion, were
more often smokers (30% vs. 24%, p = 0.01) and were less
often RF-positive (58% vs. 63%, p = 0.02) compared to the
patients who had answered the 2010 questionnaire.
Alcohol consumption data at the time of the 2010 ques-
tionnaire were available for 1,238/1,460 (85%) patients.
The 222 patients (15%) who did not answer the alcohol
questions were older, with a mean age at inclusion was 59Table 1 Demographics and disease activity variables in
the questionnaire in 2010a
Answered the 2010 postal questionnaire n = 1,460
Age in years, mean (SD) 65 (13)
Percentage females 70
HAQ 0.50 (0–1.0)
VAS global, mm 30 (10–50)
VAS pain, mm 30 (10–50)
Number of swollen joints (of 28) 1 (0–5)
Number of tender joints (of 28) 3 (1–8)
EuroQol 0.73 (0.69–0.80)
Number of current DMARDs and biologics 1.0 (1.0–2.0)
Number of previous DMARDs and biologics 1.0 (1.0–2.0)
Current methotrexate, % 60
Current glucocorticoids, % 23
Smokers, % 17
aUnless otherwise stated, data are median (interquartile range).
HAQ Health Assessment Questionnaire, VAS visual analog scale, DMARDs
disease-modifying anti-rheumatic drugs.years for those who did not answer vs. 54 years for those
who answered (p = 0.0001), had higher mean ESR (38 mm
vs. 34 mm, p = 0.03), and were more often men (37% vs.
29%, p = 0.02). There were no significant differences in
DMARD treatment or glucocorticoid treatment at base-
line, or in rheumatoid factor status or smoking status at
baseline or in 2010, between those who answered the
alcohol-related questions and those who did not.
In the entire cohort of 1,238 patients, 140 (11%) were
non-drinkers, 834 (67%) had a non-hazardous drinking,
and 264 (21%) were classified as hazardous drinkers. Sig-
nificantly more women were non-drinkers than men (14%
vs. 4%, p = 0.0001). Significantly more blue-collar workers
were hazardous drinkers (standardized residual −2.1).
Eight per cent of the patients who were non-drinkers were
current smokers, as compared to 17% of non-hazardous
drinkers and 21% of hazardous drinkers (p = 0.0001). Of
the patients ≤ 30 years of age, 39% drank heavily as com-
pared to 23% in the 31- to 65-year age group and 12% in
patients > 65 years. Older patients were more often non-
drinkers (overall p = 0.0001).
Disease activity data stratified for drinking and sex
Disease activity was stratified according to drinking and
sex (Table 2). Non-hazardous and hazardous drinkers
reported lower disease activity and higher EuroQol scores,
with the exception of SJCs. A lower proportion of hazard-
ous drinkers had undergone glucocorticoid treatment.
Women scored worse than men in all of the disease
activity variables and EuroQol (p = 0.0001 for all).
Women were also generally younger than men (64 vs.
68; p = 0.0001). Women had had significantly more
DMARDs previously than men (1.49 vs. 1.22, p = 0.0001),
and had had more previous treatment with biologics (0.3
vs. 0.2, p = 0.004). There were no significant differences in
the mean number of current DMARDs, stratified
according to gender (p = 0.61).
For women, there were significant associations between
the drinking categories and all of the disease activity va-
riables studied. However, no such differences were seen
for men (Table 2).Stratification for smoking
Current smokers only showed a significant association
between drinking and the number of SJCs (p = 0.02),
where the difference was between hazardous drinkers
and non-drinkers. Previous smokers had significant asso-
ciations between drinking and VAS global (p = 0.01),
VAS pain (p = 0.03), and HAQ (p = 0.0001), the diffe-
rences for the VAS scales being between hazardous
drinkers and non-drinkers, and for HAQ between all of
the drinking groups. For non-smokers, drinking was as-
sociated with lower disease activity in all of the variables









n = 1,238 n = 140 n = 834 n = 264 pb
Number of tender joints (of 28) 3 (1–8) 4 (1–11) 3 (1–8) 3 (1–7) 0.02
Men 2 (0–6) 2 (0–5) 2 (0–6) 2 (0–5.25) 0.94
Women 4 (1–10) 5 (2–12) 4 (1–9) 3 (1–7.25) 0.03
Number of swollen joints (of 28) 1 (0–5) 2 (0–6) 2 (0–5) 1 (0–4) 0.11
Men 0 (0–3) 0 (0–1) 0 (0–4) 1 (0–3) 0.31
Women 2 (0–6) 2 (0–6) 2 (0–6) 1 (0–4) 0.05
VAS global, mm 30 (10–50) 40 (20–50) 30 (10–50) 20 (10–40) 0.0001
Men 20 (10–50) 20 (10–45) 20 (10–40) 20 (10–40) 0.69
Women 30 (10–50) 40 (20–60) 30 (20–50) 20 (10–40) 0.0001
VAS pain, mm 30 (10–50) 40 (20–60) 30 (10–50) 30 (10–50) 0.001
Men 30 (10–50) 30 (20–40) 20 (10–40) 20 (0–40) 0.18
Women 40 (20–60) 40 (20–60) 30 (20–50) 30 (10–60) 0.03
EuroQol 0.76 (0.69–0.80) 0.73 (0.62–0.80) 0.76 (0.69–0.80) 0.80 (0.73–0.80) 0.0001
Men 0.80 (0.73–0.85) 0.73 (0.67–0.80) 0.80 (0.73–0.85) 0.80 (0.73–1.0) 0.07
Women 0.73 (0.66–0.80) 0.73 (0.59–0.80) 0.73 (0.69–0.80) 0.80 (0.73–0.80) 0.005
HAQ 0.38 (0–0.90) 0.75 (0.25–1.38) 0.5 (0–0.88) 0.25 (0–0.75) 0.0001
Men 0.25 (0–0.75) 0.13 (0–0.44) 0.25 (0–0.63) 0.13 (0–0.75) 0.80
Women 0.63 (0.13–1.239 0.88 (0.34–1.38) 0.50 (0.13–1.0) 0.38 (0–0.75) 0.0001
Number of current DMARDs and biologics,
mean (SD)
1.1 (0.8) 0.9 (0.9) 1.1 (0.7) 1.2 (0.8) 0.03
Men 1.0 (0.7) 1.1 (0.7) 1.0 (0.7) 1.2 (0.7) 0.30
Women 1.1 (0.8) 0.9 (0.9) 1.1 (0.7) 1.1 (0.9) 0.02
Number of previous DMARDs and
biologics,
mean (SD)
1.7 (1.4) 1.5 (1.2) 1.8 (1.5) 1.7 (1.3) 0.18
Men 1.0 (0.7) 1.3 (0.5) 1.5 (1.3) 1.6 (1.1) 0.24
Women 1.8 (1.5) 1.5 (1.2) 1.9 (1.6) 1.8 (1.3) 0.03
aUnless otherwise stated, data are median (interquartile range).
bThe p-values relate to the different drinking categories.
HAQ Health Assessment Questionnaire, VAS visual analog scale, DMARDs disease-modifying anti-rheumatic drugs.
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the data not shown).
Treatment with DMARDs and glucocorticoids
There were significant differences in DMARD and
glucocorticoid treatment, stratified according to alcohol
consumption. At 6 months of follow-up, 19% of the
non-drinkers had not received any DMARD treatment,
as opposed to 8% of hazardous drinkers. At 2 years of
follow-up, 25% of the non-drinkers had not received
DMARDs, as opposed to14% of the hazardous drinkers.
Hazardous drinkers more often received combination
treatment: 18% vs. 7% for non-drinkers. At 5 years of
follow-up, 31% of non-drinkers had not received any
DMARDs, as opposed to 15% of the hazardous drinkers.
Hazardous drinkers more often received biologics: 21%vs. 11%. At 8 years of follow-up, 39% of non-drinkers
had not received DMARDs, as opposed to18% of hazar-
dous drinkers. Hazardous drinkers more often received
biologics: 26% vs. 13%. Thus, non-drinkers received
DMARDs, biologics, and combination treatment less often
than hazardous drinkers.
There was no significant difference in glucocorticoid
treatment at any time point, stratified according to alcohol
consumption. There was no association between previous
or current use of methotrexate and drinking (p = 0.92 and
p = 0.13, respectively).
Multiple logistic regression analyses
Drinking at the time of the 2010 questionnaire was not
independently associated to a better outcome in VAS
global, EuroQol, or HAQ (Table 3). However, when
Table 3 Odds ratios (OR) and 95% confidence intervals (95% CI) for multivariable analyses of factors potentially
associated to VAS global, EuroQol and HAQ
VAS global EuroQol HAQ
OR (95% CI) OR (95% CI) OR (95% CI)
Sex Women 1.0 1.0 1.0
Men 0.59 (0.43–0.82) 2.09 (1.50–2.93) 0.45 (0.32–0.63)
Age 1.02 (1.01–1.04) 0.98 (0.97–0.99) 1.04 (1.03–1.06)
Disease duration 1.04 (1.01–1.08) 1.00 (0.96–1.04) 1.06 (1.02–1.10)
Alcohol use
None 1.0 1.0 1.0
Non-Hazardous 0.72 (0.43–1.20) 1.24 (0.74–2.07) 0.92 (0.55–1.53)
Hazardous 0.64 (0.36–1.16) 1.48 (0.82–2.68) 0.70 (0.38–1.26)
Socio-economic group
Blue collar 1.0 1.0 1.0
Lower white collar 0.69 (0.51–0.92) 1.54 (1.14–2.08) 0.81 (0.60–1.10)
Upper white collar 0.44 (0.25–0.80) 1.56 (0.88–2.79) 0.64 (0.36–1.16)
Self-employed 2.58 (0.51–13.10) 5.81 (0.69–48.74) 0.35 (0.07–1.79)
Others 0.88 (0.31–2.47) 1.04 (0.34–3.12) 0.54 (0.18–1.66)
Smoking Never 1.0 1.0 1.0
Previous 0.79 (0.57–1.08) 0.95 (0.68–1.32) 1.02 (0.73–1.42)
Current 1.06 (0.70–1.61) 0.58 (0.38–0.88) 1.46 (0.95–2.26)
No. DMARDs or biologics 1.15 (1.04–1.28) 0.71 (0.63–0.79) 1.51 (1.34–1.71)
Bergman et al. BMC Musculoskeletal Disorders 2013, 14:218 Page 5 of 8
http://www.biomedcentral.com/1471-2474/14/218socioeconomic class and previous treatment with
DMARDs and biologics were omitted in the regression
analyses, hazardous alcohol consumption was associated
with better EuroQol outcome (OR = 1.67, 95% CI = 1.02–
2.75, p = 0.04), better HAQ outcome (OR = 0.53, 95%
CI = 0.32–0.86, p = 0.01), and better VAS global out-
come (OR = 0.60, 95% CI = 0.37–0.98, p = 0.04).
Current smoking emerged as an independent negative
prognostic factor, but only when using EuroQol as
outcome, and only when omitting socioeconomic class
and previous anti-rheumatic treatment from the model
(data not shown).
Kind of alcohol and disease activity
In the 2010 postal self-completion questionnaire, the pa-
tients were asked what kind of alcohol they preferred to
drink. Data for this were available for 1,218/1,460 (83%)
of the patients. Two hundred and six (16.9%) preferred
to drink beer, 791 (64.9%) preferred to drink wine, and
76 (6.2%) preferred to drink spirits. A total of 145
(11.9%) drank mixed kinds of alcohol. Of the patients
who drank beer, 17% were hazardous drinkers; of the
patients who drank wine, 25% were hazardous drinkers;
of the drinkers of spirits, 18% drank hazardously; and of
those who drank different kinds of alcohol, 33% were
hazardous drinkers (p = 0.009). Men preferred to drink
beer (31%), wine (37%), spirits (11%), or more than onekind of alcohol (21%) whereas women preferred to drink
wine (78%), but not beer (10%), spirits (4%), or more
than one kind (8%) (p = 0.0001). There was no signifi-
cant association between the kind of alcohol and the
disease activity variables in the 2010 postal questionnaire
(EuroQol, p = 0.96; HAQ, p = 0.33; TJC, p = 0.65; SJC,
p = 0.49; VAS global, p = 0.76; VAS pain, p = 0.71). This
did not change when stratified for gender or the quan-
tity of alcohol consumed.Discussion
This is the first Swedish study to find an association bet-
ween drinking and disease activity in RA. Drinking was
assessed by the AUDIT-C, a validated self-completion
questionnaire, in a cross-sectional manner as part of a
postal questionnaire that also assessed patient-derived
data on disease activity, HAQ, and HRQL in 2010. We
found that there was a significant association between
non-hazardous and hazardous drinking and both lower
patient-reported disease activity and higher HRQL,
confirming one of our hypotheses. However, this effect
was only seen in women, a result that we find very sur-
prising. We could not confirm our second hypothesis,
that hazardous drinkers have poor outcome. On the
contrary, women who drank most reported lowest
disease activity and highest HRQL.
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cause and effect regarding alcohol consumption and
disease activity in our cross-sectional setting. It is possible
that women who had less joint inflammation and better
health allowed themselves to drink more. There may also
be gender differences in how women and men abstain
from drinking because of their RA; for example we were
able to show that women were more often non-drinkers
than men. We could also show that non-drinkers less
often received DMARDs, biologics, and combination treat-
ment than hazardous drinkers. This may reflect the fact
that these patients might have had more comorbidities
and/or that it was not possible to use anti-rheumatic medi-
cation due interactions with other medications, factors
that we could not adjust for. It is also possible that some
non-drinking patients chose not to use anti-rheumatic
medications. Methotrexate treatment was not associated
with drinking in our study. Men drank spirits and beer
more often than women, who preferred wine, and in men
this may possibly have been associated with hazardous
drinking during weekends, which we could not control for
in this study. There may also be physiological differences
in how men and women react to alcohol. Women had
higher disease activity, as reported earlier from this same
material [28,29], which could affect treatment decisions
and drinking patterns.
Drinking was not independently associated to a better
outcome in our regression models. However, when
socioconomic status and previous anti-rheumatic treat-
ment were omitted from the regression models, hazard-
ous drinking was associated with better global health,
HAQ, and EuroQol. There is most likely an interaction
between socioeconomic factors and alcohol.
We found that 20% of the patients were hazardous
drinkers. The real number of hazardous drinkers (running
the risk of having psychosocial problems and organ
damage) was most likely even higher. Self-reporting of al-
cohol consumption is known to give an underestimate of
drinking [21].
Alcohol is known as an immunosuppressant in both
mice [1] and humans [30]. Heavy drinking has been asso-
ciated with elevated levels of TNF-α, IL-1, and IL-6 [31],
whereas intake of low to moderate amounts of alcohol over
a longer time period (years) has been shown to reduce
levels of TNF-α, IL-1, and CRP [32,33]. Alcohol also has
anti-nociceptive effects [34]. There is thus a theoretical
background for association of alcohol consumption with
less inflammation in RA.
RA patients who smoked did not show any association
between drinking and disease activity, with the exception
of lower SJCs. This was also an unexpected finding. We
have previously reported, in this same cohort [29,35]
and also in RA patients treated with anti-TNF [36], that
RA patients who smoke have poorer prognosis. Otherstudies have confirmed this [37-44]. Current smoking
also emerged as an independent negative prognostic fac-
tor in this study, but only for the outcome EuroQol, and
only when omitting socioeconomic class and previous
anti-rheumatic treatment from the models. It is possible
that smoking causes more inflammation, or that smok-
ing interacts with the mechanisms driving inflammation,
and that alcohol as an immunosuppressant is not able to
suppress this. Lifestyle factors may also be involved.
Smoking and drinking may also be linked to poorer drug
adherence and poorer compliance.
We could see no association between the kind of alco-
hol consumed and disease activity or HRQL, and could
thus not confirm our third hypothesis that patients who
preferred to drink wine would do better. There is pre-
sently no consensus in the literature on the effects of kind
of alcohol consumed on health [45].
To what extent can our results in Sweden be genera-
lized? The Swedish multicenter EIRA case–control study
on RA reported that a lower risk of developing RA was
associated with alcohol consumption [5]. The patients in
that study drank a mean of 2.9 drinks per week [5]. The
EIRA study reported that 15% were non-drinkers, 56%
were low consumers, 14% were moderate consumers,
and 14% were high consumers, figures that are compa-
rable to ours.
How generalizable is this study internationally? A large
Swiss longitudinal observational study involving 2,903 RA
patients found a trend of reduced radiographic progres-
sion in drinkers, specifically in occasional drinkers and
those who consumed alcohol on a daily basis, as com-
pared to non-drinkers. There were gender differences.
Men who drank alcohol showed a more pronounced re-
duction in radiographic progression than men who did
not drink, whereas in women drinking had no significant
influence on radiographic outcome [3]. Thirty-seven per
cent of patients in the Swiss study were non-drinkers,
which is considerably more than the 11% in our study. Of
the patients in the Swiss study who drank alcohol, 82%
were occasional drinkers, 15% were daily drinkers, and 3%
were heavy drinkers. HAQ at baseline was higher in the
Swiss study (1.0–1.3 in that study, as compared to 0.5 in
our study) and more patients were on glucocorticoids
(about 50% in the Swiss study as compared to 23% in our
study) but a comparable number of patients were on
methotrexate (61%) [3].
A study from the UK on 873 RA patients and 1,004 con-
trols showed that the risk of developing RA decreased
according to the level of alcohol consumption, and that
measures of disease activity such as CRP, DAS28, VAS
pain, mHAQ (modified HAQ), and Larsen score were in-
versely associated with increasing frequency of alcohol
consumption in both men and women [2]. In the UK
study, a higher percentage of patients (37%) than in our
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month, 15% drank 6–10 days a month, and 16% drank > 10
days a month. Mean range of HAQ was 0.75–1.0, which
was higher than in our study, and that for DAS28CRP was
4.0–4.3 [2]. Our study differs from these earlier studies in
that the association between drinking and disease activity
and HRQL was evident only in women.
It is a limitation that we do not have any physician
derived measurement of disease activity and have to rely
on patient reports from the questionnaire, where VAS
global and HAQ could represent other aspects of the
disease than an active inflammation. We also use patient-
derived joint counts. A recent study has assessed the cor-
relations between physician- and patient-derived joint
counts in 47 RA patients treated with adalimumab. It
showed that the correlation was good for the TJCs and
SJCs at baseline (r = 0.87 and r = 0.75) and at 3 months
for the TJCs (r = 0.87), but it was somewhat less strong
for SJCs (r = 0.58) [46]. A poor correlation between
physician- and patient-derived data was found in another
study (particularly for low SJCs in the hands) in 447 RA
patients using etanercept (r = 0.08–0.55) but there was a
stronger correlation for TJCs (r = 0.78) [47]. Selection bias
may also be an issue, but 69% of eligible patients res-
ponded to the questionnaire. There were small but statis-
tically significant differences at inclusion between those
who answered the questionnaire and those who did not.
These differences are not likely to change the main fin-
dings of this study.
The major strengths of the present study were that we
had a large, well-documented patient material and that
we used a validated instrument to measure drinking
(AUDIT-C). We had a high response rate for both the
2010 questionnaire as a whole (73%) and for the alcohol
questions (85%). Our data showed that patients who did
not answer the questionnaire had higher disease activity
and were more often men, confirming earlier studies on
attrition and non-response to questionnaires [48-50].
The patients who died or who did not answer the ques-
tionnaire may also have consumed more alcohol.
Conclusions
There was an association between alcohol consumption
and both lower self-reported disease activity and higher
HRQL in female, but not male, RA patients in Sweden.
For current smokers, alcohol consumption was only as-
sociated with fewer swollen joints. We could not see any
effect of the kind of alcohol consumed on disease activ-
ity. Twenty-one per cent of the RA patients in this study
drank hazardously, a figure that is probably an under-
estimate, and which we find alarming.
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